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ABSTRACT 
Type 1 diabetes mellitus results from the autoim- 
mune and inflammatory destruction of insulin- 
producing islet  cells, rendering individuals 
devoid of insulin production. Recent studies 
suggest that combination therapies consisting 
of anti-inflammatory agents and islet growth- 
promoting factors have the potential to cause 
sustained recovery of  cell mass, leading to 
amelioration or reversal of type 1 diabetes in 
mouse models. In this study, we hypothesized 
that the combination of the anti-inflammatory 
agent lisofylline (LSF) with an active peptide 
fragment of islet neogenesis associated protein 
(INGAP peptide) would lead to remission of type 
1 diabetes in the non-obese diabetic (NOD) 
mouse. We treated groups of spontaneously 
diabetic NOD mice with combinations of LSF, 
INGAP peptide, or control saline parenterally for 
up to 6 weeks. Our results demonstrate that the 
mice receiving combined treatment with LSF 
and INGAP peptide exhibited partial remission of 
diabetes with increased plasma insulin levels. 
Histologic assessment of pancreata in mice re- 
ceiving combined therapy revealed the pre- 
sence of islet insulin staining, increased  cell 
replication, and evidence of Pdx1-positivity in 
ductal cells. By contrast, diabetic animals show- 
ed severe insulitis with no detectible insulin or 
Pdx1 staining. We conclude that the novel 
combination treatment with LSF and INGAP pe- 
ptide has the potential to ameliorate hypergly- 
cemia in the setting of established type 1 dia- 
betes via the recovery of endogenous  cells  
and warrant further studies. 
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1. INTRODUCTION 
Type 1 diabetes mellitus (T1DM) is an autoimmune 
disorder characterized by inflammatory damage to pan- 
creatic  cells resulting in loss of insulin secretion. The 
lack of insulin producing  cells results in disrupted glu- 
cose homeostasis, which leads to micro- and macrovas- 
cular complications. Combining interventions that block 
the relevant inflammatory reactions with one that re- 
stores  cell mass is required for reversing T1DM [1]. 
Interleukin 12 (IL-12) regulates T cell differentiation 
and Th1 cell activation [2]. Because activated T cells 
directly cause cytotoxcitity in  cells, IL-12 may directly 
or indirectly facilitate the development of T1DM [3]. 
Lisofylline (LSF) is an immunomodulator and anti-in- 
flammatory small molecule that reduces IL-12-mediated 
STAT4 signaling, effectively suppressing T-cell activa- 
tion and differentiation [4]. LSF also maintains  cell 
insulin secretory function in the presence of inflamma- 
tory cytokine insult and regulates immune cellular func- 
tion to suppress autoimmunity and prevent the onset of 
T1DM in non-obese diabetic (NOD) mice [4]. Whereas 
LSF also enhances insulin secretion in isolated islets and 
in transformed  cell lines in response to glucose stimu- 
lation in vitro [5], LSF alone was not capable of revers- 
ing autoimmune diabetes in NOD mice [6]. In recent 
studies, it was shown that combinations of LSF with the 
islet growth GLP-1 receptor agonist exendin-4 reversed 
diabetes in NOD mice, and even maintained euglycemia 
for up to 145 days after treatment withdrawal [6]. These 
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studies suggest that combinations of inflammation-mo- 
dulating agents with islet trophic factors may be one ap- 
proach in the treatment or reversal of T1DM. 
Islet neogenesis associated protein (INGAP) is a 
member of the Reg3 family of pancreatic proteins and 
regulated by transcriptional factors involved in neuroen- 
docrine lineage commitment [7]. In studies of normal 
hamsters, administration of an INGAP-derived peptide 
(corresponding to amino acids 104 - 118 of INGAP) ap- 
peared to stimulate islet neogenesis, as evidenced by 
small foci of insulin-positive islet-like clusters budding 
from intralobular and terminal ductules [8]. In strepto- 
zotocin-induced diabetes in mice, INGAP peptide ad- 
ministration also induced new islet formation and re- 
stored euglycemia [8]. We hypothesized that combination 
therapy with LSF and INGAP peptide would ameliorate 
or reverse T1DM by providing protection from inflam- 
matory destruction (via LSF) and stimulation of islet  
cell regeneration (via INGAP peptide). In this prelimi- 
nary study, we show that this combination therapy has 
promise in reducing hyperglycemia in the NOD mouse 
model of T1DM, but requires additional studies. 
2. METHODS 
2.1. Reagents 
LSF (1-(5-R-hydroxyhexyl)-3,7-dimethylxanthine) was 
provided by DiaKine Therapeutics, Inc. (Charlottesville, 
VA). INGAP peptide was provided by Kinexum Me- 
tabolics, Inc. (Harper’s Ferry, WV). LSF was dissolved 
in injectable normal saline and INGAP peptide was dis- 
solved in sterile phosphate buffer solution. 
2.2. Mice 
Eight-week-old female NOD/ShiLTJ (NOD) mice 
were obtained from Jackson Laboratories (Bar Harbor, 
ME) and maintained in a pathogen-free colony in the 
Center for Comparative Medicine under protocols ap- 
proved by the Institutional Animal Care and Use Com- 
mittee using AALAAC guidelines at the University of 
Virginia. NOD mice were monitored for diabetes by 
measuring blood glucose levels using AccuChek Advan- 
tage Glucose Monitors (Roche, Indianapolis, IN) with 
tail vein blood samples. Non-fasting blood glucose val- 
ues > 250 mg/dL for 3 consecutive days were considered 
as evidence of diabetes onset.  
2.3. Treatments 
Spontaneously diabetic NOD mice, between 12 - 25 
weeks of age, were implanted with sustained release bo- 
vine insulin pellets (LinShin, Ontario, Canada). The in- 
sulin pellets have a release rate of ~0.1 U/24hr/pellet for 
30 days and were used at 1/4, 1/2, and single doses. Insu 
lin pellets were immersed briefly in 2% povidone-iodine 
solution before being implanted subcutaneously using a 
12-gauge trocar while under anesthesia. Insulin pellets 
were supplied to the mice to maintain blood glucose 
values around 200 mg/dL. Blood glucose values were 
monitored a minimum of twice a week to ensure eugly- 
cemia. If a mouse had a biweekly reading above 300 
mg/dL the mouse received another dose of insulin pellet 
to help maintain euglycemia, if the biweekly reading was 
below 125 mg/dL, insulin pellets were removed. All 
treatments started within 3 - 5 days after diabetes was 
initially diagnosed (defined as a blood glucose >250 
mg/dL on three consecutive readings). LSF was deliv- 
ered at 27 mg/kg/day or saline control via Alzet osmotic 
mini-pumps (DURECT Co., Cupertino, CA). Each mini- 
pump was placed subcutaneously on the back of a mouse 
that was under general anesthesia; mini-pumps were re- 
placed every two weeks. INGAP was administered by 
intraperitoneal (IP) injection at 500 µg/day once daily for 
6 weeks. Groups were as follows: Group A mice received 
saline pumps for four weeks and saline IP injections for 6 
weeks; Group B mice received LSF pumps for 4 weeks 
and saline IP injections for 6 weeks; Group C mice re- 
ceived saline pumps for 4 weeks and INGAP IP injec- 
tions for 6 weeks; Group D mice received LSF pumps 
for 4 weeks and INGAP IP injections for 6 weeks; Group 
E mice received LSF pumps for 6 weeks and INGAP IP 
injections for 6 weeks, INGAP was started one week 
after the initial LSF pump (see Figure 1(a)). All treat- 
ment groups were kept on insulin pellets during the 
course of treatment. After six weeks of treatment (mice 
in Group E were treated for a total of 7 weeks), insulin 
pellets were surgically removed and mice were moni- 
tored one week before euthanasia. Final blood glucose 
values were measured the day of euthanasia between 9 - 
10 am in the morning.  
2.4. Immunohistochemisty and  
Immunofluorescence 
Pancreas isolation and tissue embedding proceeded as 
previously described [9]. Antibodies and dilutions were 
as follows: insulin (1:5000, Dako, Carpinteria, CA), 
Pdx1 (1:800, Millipore, Temecula, CA), Ki67 (1:500, 
Abcam, Cambridge, MA), anti-rabbit Alexa Fluor 555 
(1:500, Invitrogen, Carlsbad, CA), and anti-guinea pig 
Alexa Fluor 488 (1:200, Invitrogen, Carlsbad, CA). All 
sections were stained with Hoechst Dye (5 µl/mg; Invi- 
trogen, Carlsbad, CA) to visualize the nucleus. Digital 
images were acquired on an Axio-Observer Z1 micro- 
scope (Zeiss, Thornwood, NY) fitted with an AxioCam 
high resolution color camera. Florescence sections were 
acquired on an Olympus BX51 WI fluorescence micro- 
scope (Olympus, Tokyo, Japan) fitted with a Hamamatsu  
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(c) 
Figure 1. Reversal of diabetes in mice treated with LSF and 
INGAP. (a) Schematic representation of the treatment protocol 
and group identification; (b) Non-fasting final blood glucose 
values of treated mice at the end of the study. The detection 
limit for the glucometer is 600 mg/dlL; (c) Non-fasting serum 
insulin levels of treated mice one week after stopping treatment 
(n = 6 - 8 per group). Non-diabetic NOD mice (ND) were used 
as non-diabetic controls. The “*” indicates that the values are 
statistically different (P < 0.05) compared to the value for the 
saline-treated diabetic mice (Group A). 
 
ORCA-ER monochrome charged-coupled device camera 
(Hamamatsu Photonics, Iwata City, Japan). 
2.5. Insulin Measurements 
At time of euthanasia, blood was obtained by cardiac 
puncture. Serum insulin concentrations were determine 
by mouse insulin ELISA (Mercodia, Winston Salem, NC) 
and quantitated against a standard curve.  
2.6. Statistics 
Data are shown as mean ± SEM. One-way ANOVA 
(with Bonferroni post-test) was used for data analysis 
using GraphPad Prism (version 5.0) software. P values of 
less than 0.05 were considered significant. 
3. RESULTS 
3.1. Glycemic Control Is Improved in  
Animals Treated with Combinations of  
LSF and INGAP Peptide 
Groups of 6 - 8 female NOD mice were started on one 
of five treatments after being diagnosed with diabetes 
(defined as a blood glucose >250 mg/dl on three conse- 
cutive readings). There was no difference in starting 
blood glucose values between all treatment groups (Ta- 
ble 1). Diabetic mice were randomly assigned into one of 
five groups: saline/normal control (Group A), LSF alone 
(Group B), INGAP alone (Group C), INGAP plus LSF 
(Group D), and LSF pretreatment plus INGAP (Group E; 
treatment for 7 days with LSF, followed by dual treat- 
ment with both LSF and INGAP; see Figure 1(a)). All 
mice received a sustained release insulin pellet during 
the treatment period to reduce the complications associ- 
ated with severe hyperglycemia. Blood glucose values 
were maintained at an average of 223 ± 7.1 mg/dL 
throughout the course of treatment for all groups.  
After initiation of drug treatment, mice in the combi- 
nation treatment groups, D and E required fewer insulin 
pellets to maintain near normal glycemia compared to 
any other group, suggestive of partial recovery from  
 
Table 1. Blood glucoses at the start and during treatment of 
NOD mice. 
Treatment 
Groupa 
Starting Blood 
Glucose 
(mg/dL) 
Blood Glucose  
during Treatment 
(mg/dL) 
Number of 
Insulin Pellets 
Required 
A 386 ± 55 250 ± 24 2.5 ± 0.2 
B 381 ± 30 258 ± 15 2.3 ± 0.2 
C 355 ± 30 185 ± 16 2.6 ± 0.3 
D 350 ± 25 194 ± 14 1.7 ± 0.4 
E 357 ± 20 265 ± 13 1.1 ± 0.2* 
aTreatment groups: (A) saline/normal control; (B) LSF alone; (C) INGAP 
alone; (D) INGAP plus LSF; (E) treatment for 7 days with LSF, followed by 
dual treatment with both LSF and INGAP. 
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diabetes. Only in Group E did the reduction in pellets 
achieve statistical significance (Table 1). At the end of 
treatment, insulin pellets were removed and animals 
were monitored for seven days to determine their glyce- 
mic state. As shown in Figure 1(b), mice in Groups B-D 
averaged blood random glucoses in excess of 400 mg/dL 
upon removal of the insulin pellets, and were statistically 
no different from saline treated control animals (Group 
A). Importantly, however, animals in Group E (which 
were pretreated one week with LSF) averaged 280 mg/dL, 
a value that while modest, was significantly lower than 
saline-treated controls (Group A) (Figure 1(b)). Impor- 
tantly, 5 out of 7 animals in Group E exhibited random 
glucoses under 250 mg/dL (defined a priori as remission) 
during the entire final week post treatment. Two of two 
mice in Group E remained euglycemic for two months 
post treatment (data not shown).  
OPEN ACCESS 
Upon completion of the study, mice were euthanized 
and random plasma mouse insulin levels were measured 
(Figure 1(c)). Although not statistically significant, there 
was a trend toward higher insulin levels in mice from 
any treatment group with INGAP (Groups C-E) (Figure 
1(c)) compared to saline controls. 
3.2. Immunohistochemical Analysis Shows  
Evidence of Islet Regeneration with  
Combination Therapy 
To assess islet growth and regeneration in treated ani- 
mals, pancreatic tissue was harvested and stained for 
insulin, Pdx1, and a marker of cell proliferation (Ki67). 
Notwithstanding evidence of insulitis with mononuclear 
cellular infiltrate around the islets, control non-diabetic 
NOD mice exhibited insulin staining in islets of pancre- 
atic sections (Figure 2). By striking contrast, pancreatic 
sections from diabetic (saline control, Group A) NOD 
mice exhibited severe islet infiltration of mononuclear 
cells and minimal to no apparent insulin staining (Figure 
2), consistent with active islet  cell destruction. In mice 
treated with combination LSF pretreatment and INGAP 
(Group E), insulin-positive cell clusters were widely dis- 
tributed throughout the pancreas despite evidence of per- 
sistent insulitis, similar to non-diabetic NOD mice. 
Consecutive tissue sections were stained for insulin 
and Pdx1, a key transcription factor involved in the dif- 
ferentiation of progenitor cells into insulin-producing 
cells. As expected, in control non-diabetic NOD mice, 
we found positive staining for Pdx1 in insulin-positive 
islets (data not shown), and no Pdx1 staining in the insu- 
lin-negative Group A islets. Interestingly, in group E 
mice, whereas insulin-positive cells were also positive 
for Pdx1, we also observed Pdx1-positivity in many pan- 
creatic ductal cells (Figure 3). Pdx1 staining in pancre- 
atic ducts was not observed in non-diabetic controls or in 
pancreata from Group A. 
3.3. Combination Therapy Led to Increased  
Islet  Cell Proliferation 
Cellular proliferation was examined using immuno- 
fluorescence staining for Ki67 and insulin. As shown in 
Figure 4, there were no detectable Ki67/insulin co- 
staining cells in non-diabetic NOD mice or in Group A 
mice, although Ki67 positivity was abundant in the dense 
 
 
Figure 2. Treatment of NOD mice with LSF and INGAP restored islet insulin positivity. Pancreata were stained 
for insulin (brown) and counterstained with hematoxylin (blue). Sections from representative pancreata from 
non-diabetic NOD, saline-treated diabetic Group A, and Group E mice are shown at low (original magnification, 
× 100; top panels) and high (original magnification, × 630; bottom panels) magnification. 
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Figure 3. Mice treated with LSF and INGAP displayed Pdx1+ cells in the ducts. Sections of pancreata were 
stained with Pdx1 (original magnification, × 630). Pdx1 + cells in the duct are indicated by arrows. 
 
 
Figure 4. Islet β cell proliferation is increased with LSF and INGAP combination therapy. Pancreata were har-
vested from the groups of mice indicated, and representative sections stained for Ki67 (red), insulin (green), and 
DAPI (blue) and are shown (original magnification, × 630). 
 
peri-islet mononuclear infiltrate. By contrast, frequent 
Ki67/insulin co-staining cells were observed within insu- 
lin positive cells in mice from Group E, indicating the 
presence of proliferating  cells. 
4. DISCUSSION 
T1DM is caused by autoimmune activation of T cells 
and macrophages, leading to the inflammatory destruc- 
tion of islet  cells. Although suppression of the inflam- 
matory and autoimmune responses is crucial in any ap- 
proach to cure T1DM, it is also clear that islet trophic 
factors will be necessary to augment the islet mass that is 
severely compromised in long-standing T1DM [1,10]. 
Recent studies support this approach in NOD mice. 
Studies of Yang, et al. demonstrated successful reversal 
of T1DM in this model using combinations of the anti- 
inflammatory compound LSF and the growth factor ex- 
endin-4 [6]. More recently, studies of Tian et al. demon- 
strated that successful reversal of T1DM in NOD mice 
by use of a dipeptidyl-peptidase IV inhibitor was likely 
though a combination effect of the drug on T regulatory 
cells and islet proliferation [11]. In this study, we tested 
the hypothesis that a combined administration of the 
anti-inflammatory agent LSF with the islet neogenesis 
factor INGAP peptide would ameliorate T1DM in dia- 
betic NOD mice.  
LSF appears to target inflammatory pathways by in- 
hibiting IL-12-mediated STAT4 signaling [4]. IL-12 is 
important in activating Th1 cells and promoting their 
release of pro-inflammatory cytokines [3]. Prior studies 
have shown that LSF can prevent the development of 
autoimmune diabetes in NOD mice [4] and protect trans- 
planted islets from destruction [12]. However, and con- 
sistent with prior studies [6], we show here that LSF 
alone was not capable of reversing diabetes in NOD 
mice. 
INGAP peptide has been shown to stimulate prolifera- 
tion and growth of islets, and to protect against the de- 
velopment of hyperglycemia in the streptozotocin model 
of diabetes in mice [8]. The administration of INGAP 
peptide in combination with immunosuppressants (tac- 
rolimus and sirolimus) in NOD mice led to improve- 
ments in glycemic control [13], but its utility as a single 
agent in NOD mice has not been studied. We show here 
that a 6 week treatment with either LSF or INGAP pep- 
tide alone is not sufficient to reverse hyperglycemia in 
this model, a finding that likely suggests that growth 
factors for this period alone may be insufficient to re- 
verse diabetes in this model. In a clinical trial INGAP 
increased arginine-stimulated C-peptide release during 
the treatment phase of type 1 diabetic subjects, but this 
effect was lost after 30 days of drug wash-out [14]. The 
authors raised the possibility that this was due to persis- 
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tent autoimmune destruction of newly-formed  cells. To 
overcome this limitation, we combined use of INGAP 
peptide with LSF as a modulator of the inflammation 
process. 
Both of our treatment groups involving combined LSF 
and INGAP peptide administration appeared to reduce 
non-fasting glucose levels compared to control animals, 
but this result was statistically significant only in the 
mice that were pre-treated for one week with LSF prior 
to starting combination therapy with the two drugs 
(Group E). Our rationale for this pre-treatment phase was 
to reduce systemic inflammation prior to the induction of 
islet neogenesis with INGAP peptide. A particularly no- 
table observation in our studies was that the remission in 
Group E occurred independent of the level of starting 
serum glucose, suggesting that amelioration of T1DM 
was possible even when animals were severely hyper- 
glycemic (>350 mg/dl) prior to the start of treatment. 
Insulin, Pdx1, and Ki67 staining was utilized to ex- 
amine cell differentiation and proliferation in the treated 
NOD mice. We found insulin/Ki67 co-expressing cells in 
pancreata of Group E animals, a finding suggestive of  
cell proliferation. Pdx1 is a  cell-specific transactivator 
of the insulin genes and is necessary for the development 
of the pancreas and for the maintenance of  cells in the 
adult (for review, see [15]). Activation of Pdx1 has been 
seen in the duct cells of the pancreas following partial 
pancreatectomy in mice [16]. Prior studies showed that 
INGAP enhanced the differentiation of pancreatic duct 
cells in vitro into islet-like clusters [8,17]. Here, we show 
increased foci of Pdx1 staining, mostly within ducts (al- 
though some Pdx1 staining was also seen in the acinar 
compartment). Although the significance of this finding 
is inconclusive, it is possible that INGAP treatment com- 
bined with lisofylline could allow for potential neogene- 
sis from these Pdx1-positive/insulin-negative cells. 
This study represents an initial attempt at combining 
the inflammatory modulator, LSF and the growth factor, 
INGAP in the treatment of T1DM in NOD mice. 
Through a limited series of experiments our results sug- 
gest that combination therapies involving inflammatory 
modulators and growth factors have the potential to ame- 
liorate or reverse T1DM in mice. More importantly, our 
studies suggest the efficacy of a novel combination of 
drugs, both of which have undergone early safety studies 
in humans. These early results are modest, but encour- 
aging and suggest a more in-depth study to eliminate the 
limitations of this study. More animals per group and a 
standard glucose tolerance test including fasting blood 
glucoses and insulin levels are needed to determine the 
rate of remission with this treatment in NOD mice. 
Quantitative  cell mass and Ki67 staining is necessary 
to determine if indeed LSF plus INGAP is increasing  
cell proliferation, as suggested by our preliminary re- 
sults. 
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